2019
Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy
LOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.Peer-Reviewed Original ResearchConceptsLocoregional recurrence-free survivalAdjuvant therapyNeck squamous cell carcinomaOutcomes of patientsRecurrence-free survivalSquamous cell carcinomaNeck cancer patientsHNSCC patientsClinical outcomesRecurrence rateCell carcinomaMean TTPCancer patientsPatientsTherapyResectionMonthsOutcomesHNSCCSurgeryCarcinomaHeadIncidenceProgression
2017
The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma
Schutt CA, Mirandola L, Figueroa JA, Nguyen DD, Cordero J, Bumm K, Judson BL, Chiriva-Internati M. The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma. Oncotarget 2017, 5: 100280-100287. PMID: 29245977, PMCID: PMC5725019, DOI: 10.18632/oncotarget.22213.Peer-Reviewed Original ResearchNeck squamous cell carcinomaAutologous dendritic cellsAutologous tumor cellsSquamous cell carcinomaHNSCC patientsCancer-testis antigensDendritic cellsCell carcinomaNon-small cell lung cancerTumor cellsSp17 expressionIdeal immunotherapeutic targetSpecific cytotoxic lymphocytesCell lung cancerCurrent treatment modalitiesPotential serological biomarkerSperm protein 17Possible future targetsTherapeutic vaccinesImmunotherapeutic targetPoor prognosisAggressive malignancyMultiple myelomaPeripheral bloodTNM stage